同种异体自然杀伤细胞疗法
本综述聚焦同种异体自然杀伤(NK)细胞疗法,以规避自体CAR-T细胞生成周期长、成本高、异质性与毒性等问题。NK细胞可来自外周血、脐带血、造血干祖细胞或诱导多能干细胞,可扩增冻存实现现货供应;早期临床试验显示同种异体NK细胞产品初步结果令人鼓舞。文章详述NK细胞生物学、产品制造、工程化改造及临床联合治疗策略。
要点
- NK细胞固有识别肿瘤且不诱导移植物抗宿主病、细胞因子释放综合征或免疫效应细胞相关神经毒性综合征。
- NK细胞可源于血液、脐带血、造血干祖细胞或诱导多能干细胞,可扩增冻存实现现货供应。
- 基础进展推动阻断抑制信号、增强靶细胞识别、优化功能持久性及逃逸患者免疫的转化策略。
核心结论
- 同种异体NK细胞产品早期临床试验初步结果令人鼓舞,基础与工程化进展正推动下一代现货型血液肿瘤细胞疗法。
研究设计与样本
- 综述,总结NK细胞生物学、产品制造、工程化改造及临床联合治疗策略。
主要发现
- 自体T细胞产品存在生成需数周、供者与患者1:1模式、昂贵、异质性与生产失败等局限。
- CAR-T细胞与显著毒性相关,包括细胞因子释放综合征、免疫效应细胞相关神经毒性综合征和持续性血细胞减少。
- NK细胞固有识别肿瘤、介导杀伤与通讯免疫功能,且不诱导移植物抗宿主病、细胞因子释放综合征或免疫效应细胞相关神经毒性综合征。
- NK细胞可自血液或脐带血获取,或源自造血干祖细胞或诱导多能干细胞,可扩增冻存实现现货供应。
- 首波床旁NK细胞疗法推动当前同种异体NK细胞产品进入临床试验,初步结果令人鼓舞。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interest in adoptive cell therapy for treating cancer is exploding owing to early clinical successes of autologous chimeric antigen receptor (CAR) T lymphocyte therapy. However, limitations using T cells and autologous cell products are apparent as they (1) take weeks to generate, (2) utilize a 1:1 donor-to-patient model, (3) are expensive, and (4) are prone to heterogeneity and manufacturing failures. CAR T cells are also associated with significant toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and prolonged cytopenias. To overcome these issues, natural killer (NK) cells are being explored as an alternative cell source for allogeneic cell therapies. NK cells have an inherent ability to recognize cancers, mediate immune functions of killing and communication, and do not induce graft-versus-host disease, cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome. NK cells can be obtained from blood or cord blood or be derived from hematopoietic stem and progenitor cells or induced pluripotent stem cells, and can be expanded and cryopreserved for off-the-shelf availability. The first wave of point-of-care NK cell therapies led to the current allogeneic NK cell products being investigated in clinical trials with promising preliminary results. Basic advances in NK cell biology and cellular engineering have led to new translational strategies to block inhibition, enhance and broaden target cell recognition, optimize functional persistence, and provide stealth from patients' immunity. This review details NK cell biology, as well as NK cell product manufacturing, engineering, and combination therapies explored in the clinic leading to the next generation of potent, off-the-shelf cellular therapies for blood cancers.
引用
- Berrien-Elliott MM, Jacobs MT, Fehniger TA, et al. Allogeneic natural killer cell therapy. Blood. 2023. PMID: 36416736. doi:10.1182/blood.2022016200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。